Hikma Pharmaceuticals Share Discussion Threads

[odys2] 17/3/2011 14:21

Topped up as planned.

[odys2] 15/3/2011 13:19

Hikma will announce its preliminary results for the year ended 31 December 2010 on Wednesday 16 March 2011.
Panic selling all over the stock market is understandable after the earthquake. Support at 700 is still holding.
Top up time? Or would it be better to wait till tomorrow for the preliminary results reaction first? I'd rather wait for a convincing buy signal.

[fig1] 28/1/2011 12:18

worries over middle-east street protests?fig.

[hannabella] 05/1/2011 15:14

Going well today

[odys2] 12/11/2010 16:13

Naked Trader writes today:


"Stocks often fall on a statement day even if the statement is good.

It's often profitable to buy in once the profit takers have gone. Either late the same day or a couple of days later.

So I just bought some more Hikma (HIK) for a spreadbet fiver at 748 to add to the ones I got in the 720s. It looks like it might have bottomed and it climbing back up. The statement didn't have any horrors and the longer term uptrend is still strong, so I've bought on the weakness. Maybe I should have waited longer - We shall see! Target 850 stop 720."

[robrah] 12/11/2010 09:30

taken off all stop and topped up :) , bring it on mm . u aint geting non of mine this time .

will hold it till 9.50

[odys2] 12/11/2010 08:46

Nothing wrong with the interim management statement. Some top up opportunities this morning.

[odys2] 03/11/2010 16:07

Robbie Burns is still holding Hikma. His todays comments from the Naked Trader website:

"Hikma came back a bit after the big rise on the acquisition news - been a nice one so far and the rise looks set to continue."

[odys2] 03/11/2010 00:14

Yes Robrah, looks like another tree shake...
Now something more - a quotation from Ukcitymedia - Newspaper share tips:

"Pharma giant Hikma announced at the end of last week that it will pay $112m for the US company Baxter. This is equivalent to around 7 times earnings, which looks good value for the pharmaceutical sector. Brokers believe Hikma shares are 23 times this year's earnings and so the Times says that they are up with events."

[robrah] 02/11/2010 15:48

seems like MM trying to drop it again but not letting this go this time . must be somemore news tomorrow .

in fact looking for a price to top up .

[odys2] 02/11/2010 00:00

Short article by topnews.co.uk published yesterday

quotes:
"Hikma Pharmaceuticals is said to be listed on the London Stock Exchange, as after the acquirement it has now become the 10th to the second biggest supplier of the drugs in the US with a 15% market share."

"Even after the $112m deal, Hikma is left with $500m which it intends to spend on facilities and expansions"

[gorilla36] 01/11/2010 09:26

Robrah - You are completely correct in your assumption, somebody always knows. It has always been the way and always will be. "Fair"...... not really, but that is the name of the game I'm afraid. Seen this a zillion times before.

[odys2] 29/10/2010 08:53

Most probably market makers collected shares yesterday to sell them dearly today.

[robrah] 29/10/2010 07:48

the massive fall yesterday 30 p and the massive jump today 50 p .

I susupect someone had this news before it was made public this morning .

it is not fair the way this work. :(

[odys2] 29/10/2010 06:49

As per todays RNS:


"The acquisition of Multi-Source Injectables:

� Brings close to $180 million in annual revenue, significantly enhancing the
scale and scope of Hikma's global Injectables platform

� Adds a high-quality, complementary injectables portfolio including
excellent critical care products and DEA controlled substances

� Positions Hikma as the second largest injectables supplier in the US1 with
a combined market share of more than 15%

� Brings well qualified and experienced operational and sales teams with
excellent technical skills and customer relationships

� Increases Hikma's high quality injectables manufacturing capacity and
distribution capabilities"

[odys2] 13/10/2010 21:13

It could be time to buy. The Naked Trader - Robbie Burn's is in. He is usually right. His followers will come to buy as well.

The quote:
"I also nabbed some Hikma (HIK) - time I got myself a bit of exposure to this sector. Fundamentals look good but even better is the lovely strong uptrend that is kicking skywards. This one's on a spreadbet for a tenner at 720. Target 800 stop 705."

[gopher] 20/9/2010 15:50

0943 GMT [Dow Jones] Numis Securities cuts Hikma PharmaceuticalsHikma Pharmaceuticals (HIK.LN) to sell from reduce after concluding 1H earnings benefited significantly from sales of a gout drug which is at risk of being pulled from the US market. The FDA granted a period of market exclusivity to a rival colchicine product and analyst Jonathan Kwok says he wouldn't be surprised if HikmaHikma's version were off the market by Christmas. He cuts sales estimates for HikmaHikma's generics unit by 30% for 2011. He notes the maker of the approved drug is pursuing HikmaHikma in the courts for loss of sales. 650p target. Shares -5.1% at 727p. ([e-mail])

[trewsa] 20/9/2010 09:42

What's gone wrong?

[dalstal] 19/1/2010 14:42

breaking it out?

[rgcol1] 28/9/2009 10:40

SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Hikma Pharmaceuticals Plc and produced a report, rating the company's attractiveness to long-term investors.


Ilhavo, Portugal – 24/09/2009 – SADIF Investment Analytics, announces a new summary due diligence report covering Hikma Pharmaceuticals Plc (HIK). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Hikma Pharmaceuticals Plc investor.

Report Summary: Hikma Pharmaceuticals Plc is an above average quality company with a neutral outlook. Hikma Pharmaceuticals Plc has


strong business growth and is run by passable management. When compared to its closest peer, Dechra Pharmaceuticals plc, Hikma Pharmaceuticals Plc shows similar overvaluation and is more likely to outperform the market.

The 8-page report breaks down the Total StockMark into its three components – business, management and price, performing an in-depth analysis of Hikma Pharmaceuticals Plc for long-term investors.

[masurenguy] 17/7/2009 06:33

RNS Number : 8131V
Hikma Pharmaceuticals Plc
17 July 2009

Hikma signs licensing agreement with Faes Farma SA for anti-histamine Bilastine

London, 16 July 2009: Hikma Pharmaceuticals PLC ('Hikma') (LSE:HIK) (NASDAQ Dubai: HIK), a leading speciality pharmaceutical company, today announces that its subsidiary Hikma Pharmaceuticals LLC has signed a licensing agreement for the anti-histamine Bilastine with FAES FARMA, S. A., a Spanish pharmaceutical company, for the Middle East & North Africa ('MENA') region. Through this agreement FAES FARMA grants exclusive rights for the manufacture and distribution of Bilastine to Hikma for 17 MENA countries, while reserving its co-marketing rights in some of them.

Bilastine is a highly selective oral anti-histamine with an excellent safety profile aimed to treat allergic rhinitis and chronic urticaria. The anti-histamine market in the MENA region is approximately $115 million and has been growing at a rate of approximately 13% (Source: IMS Health). Hikma will leverage its position as the largest regional pharmaceutical manufacturer and marketer in the MENA region with its extensive sales force of more than 1,100 sales representatives to drive sales of this important product. Hikma expects to achieve annual Bilastine sales of over $10 million after launching the product throughout its whole MENA territory. It is expected that this agreement will be followed by others between HIKMA and FAES for additional licensed products.

Said Darwazah, Hikma's Chief Executive Officer commented: 'This agreement reinforces our position as the partner of choice for marketing branded products in the MENA region. In-licensing is a key part of our growth strategy in the region and accounts for more than 30% of sales in our Branded business. We are pleased to have secured the license for this important anti-histamine and look forward to making Bilastine available to our customers across the MENA region.'